Review



got1 inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress got1 inhibitor
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Got1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+inhibitor-1/pmc12955881-68-21-23
    Average 94 stars, based on 3 article reviews
    got1 inhibitor - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer"

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    Journal: Advanced Science

    doi: 10.1002/advs.202516578

    Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Figure Legend Snippet: Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.

    Techniques Used: Inhibition, Concentration Assay, Staining, Western Blot, Activity Assay, Cell Culture

    Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.
    Figure Legend Snippet: Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Techniques Used: Inhibition

    Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.
    Figure Legend Snippet: Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Techniques Used: Derivative Assay, Inhibition, Activity Assay, Staining, Microarray

    Related Articles

    Activity Assay:

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1.
    Article Snippet: The silent information regulator T1 (SIRT1) is linked to longevity and is a crucial mediator of osteoblast function.. We investigated the direct role of Sirt1 during bone modeling and remodeling stages in vivo using Tamoxifen-inducible osteoblastspecific Sirt1 conditional knockout (cKO) mice. cKO mice exhibited lower trabecular and cortical bone mass in the distal femur.. These phenotypes were coupled with lower bone formation and bone resorption.

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. GOT1 activity inhibition To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. Statistics Statistical analyses were performed using GraphPad Prism 9.0. ..

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. .. Statistical analyses were performed using GraphPad Prism 9.0.

    Saline:

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1.
    Article Snippet: The silent information regulator T1 (SIRT1) is linked to longevity and is a crucial mediator of osteoblast function.. We investigated the direct role of Sirt1 during bone modeling and remodeling stages in vivo using Tamoxifen-inducible osteoblastspecific Sirt1 conditional knockout (cKO) mice. cKO mice exhibited lower trabecular and cortical bone mass in the distal femur.. These phenotypes were coupled with lower bone formation and bone resorption.

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. GOT1 activity inhibition To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. Statistics Statistical analyses were performed using GraphPad Prism 9.0. ..

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. .. Statistical analyses were performed using GraphPad Prism 9.0.

    Dissection:

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1.
    Article Snippet: The silent information regulator T1 (SIRT1) is linked to longevity and is a crucial mediator of osteoblast function.. We investigated the direct role of Sirt1 during bone modeling and remodeling stages in vivo using Tamoxifen-inducible osteoblastspecific Sirt1 conditional knockout (cKO) mice. cKO mice exhibited lower trabecular and cortical bone mass in the distal femur.. These phenotypes were coupled with lower bone formation and bone resorption.

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. GOT1 activity inhibition To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. Statistics Statistical analyses were performed using GraphPad Prism 9.0. ..

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. .. Statistical analyses were performed using GraphPad Prism 9.0.

    Inhibition:

    Article Title: SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1
    Article Snippet: The following antibodies were used: acetyllysine (PTM BIO, PTM-105RM) (1:1000), crotonyllysine (PTM BIO, PTM-501) (1:1000), succinyllysine (PTM BIO, PTM-1419) (1:1000), SIRT1 (Abcam, ab189494) (1:1000), SIRT1 (FineTest, Fnab07877) (1:1000), GOT1(Proteintech, 12886-1-AP) (1:1000), GOT1 (Thermo Fisher, 14886-1-AP), β-actin (Proteintech, 66009-1-lg) (1:50,000), Flag (Proteintech, 66008-4-Ig), HA (Proteintech, 51064-2-AP), goat anti-rabbit IgG (Thermo, 31460) (1:10,000), goat anti-mouse IgG (Thermo, 31430) (1:10,000), goat anti-rabbit IgG (ZHUANGZHI, EK010) (1:10,000), and goat anti-mouse IgG (ZHUANGZHI, EK010) (1:10,000). .. GOT1 activity inhibition To inhibit the activity of GOT1, mice aged 8 weeks were treated with vehicle (saline) and/or 10 mg/kg aminooxyacetic acid (AOA) (MedChemExpress, HY-107994) every other day until dissection at 16 weeks, and osteoblasts were treated with vehicle or 100 μM AOA for 48 h. Statistics Statistical analyses were performed using GraphPad Prism 9.0. ..



    Similar Products

    got1 inhibitor  (MedChemExpress)
    94
    MedChemExpress got1 inhibitor
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Got1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+inhibitor-1/pmc12955881-68-21-23
    Average 94 stars, based on 1 article reviews
    got1 inhibitor - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    anti got1  (Proteintech)
    93
    Proteintech anti got1
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Anti Got1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/10__1038_slash_s41598___026___69198___8-119-28-29
    Average 93 stars, based on 1 article reviews
    anti got1 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    partial protein fragment  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology partial protein fragment
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Partial Protein Fragment, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pm42236942-626-10-32
    Average 94 stars, based on 1 article reviews
    partial protein fragment - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    lentivirus expressing shrna targeting got1  (Shanghai Genechem Ltd)
    86
    Shanghai Genechem Ltd lentivirus expressing shrna targeting got1
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Lentivirus Expressing Shrna Targeting Got1, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/expressing+got1+lentivirus+shrna+targeting/10__1186_slash_s40001___026___04271___6-83-6-21
    Average 86 stars, based on 1 article reviews
    lentivirus expressing shrna targeting got1 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    membranes  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology membranes
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Membranes, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pm41892305-141-1-13
    Average 94 stars, based on 1 article reviews
    membranes - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    1 ap  (Proteintech)
    93
    Proteintech 1 ap
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/pm41759528-264-35-34
    Average 93 stars, based on 1 article reviews
    1 ap - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    got1  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology got1
    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes <t>(GOT1,</t> GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)
    Got1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pmc13077985-74-8-9
    Average 94 stars, based on 1 article reviews
    got1 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    got1  (Proteintech)
    93
    Proteintech got1
    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes <t>(GOT1,</t> GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)
    Got1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/pm41760625-326-50-52
    Average 93 stars, based on 1 article reviews
    got1 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Inhibition, Concentration Assay, Staining, Western Blot, Activity Assay, Cell Culture

    Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Inhibition

    Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Derivative Assay, Inhibition, Activity Assay, Staining, Microarray

    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes (GOT1, GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)

    Journal: Journal of Translational Medicine

    Article Title: FFAR4 negatively regulates colorectal cancer growth via blocking oxidative phosphorylation

    doi: 10.1186/s12967-026-07942-4

    Figure Lengend Snippet: TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes (GOT1, GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)

    Article Snippet: The primary antibodies included Cyclin D1 (Proteintech, China), GOT1 (ABclonal, China), GOT2 (ABclonal, China), MDH1 (ABclonal, China), MDH2 (ABclonal, China), OXPHOS Cocktail (Proteintech, China), and β-actin (Cell Signaling Technology, USA), all diluted 1:1000 in TBST containing 3% bovine serum albumin (BSA).

    Techniques: Gene Expression, Control, Activation Assay, Transformation Assay, Western Blot, Standard Deviation

    TUG891 suppresses tumor growth in an MC38 syngeneic mouse model. ( A ) Body weight of mice treated with PBS or TUG891 during the experimental period ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( B ) Tumor growth curves showing tumor volume over time ( n = 7). The data were expressed as the mean ± Error of the Mean (SEM). ( C ) Representative images of excised tumors at the experimental endpoint ( n = 7). ( D ) Tumor weights measured at sacrifice ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( E ) Immunofluorescence staining of FFAR4 in tumor tissues from PBS- and TUG891-treated mice. ( F ) Western blot analysis of GOT1, MDH1, and oxidative phosphorylation–related proteins (ATP5A1 and UQCRC1) in tumor tissues. ns, not significant ( P ≥ 0.05)

    Journal: Journal of Translational Medicine

    Article Title: FFAR4 negatively regulates colorectal cancer growth via blocking oxidative phosphorylation

    doi: 10.1186/s12967-026-07942-4

    Figure Lengend Snippet: TUG891 suppresses tumor growth in an MC38 syngeneic mouse model. ( A ) Body weight of mice treated with PBS or TUG891 during the experimental period ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( B ) Tumor growth curves showing tumor volume over time ( n = 7). The data were expressed as the mean ± Error of the Mean (SEM). ( C ) Representative images of excised tumors at the experimental endpoint ( n = 7). ( D ) Tumor weights measured at sacrifice ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( E ) Immunofluorescence staining of FFAR4 in tumor tissues from PBS- and TUG891-treated mice. ( F ) Western blot analysis of GOT1, MDH1, and oxidative phosphorylation–related proteins (ATP5A1 and UQCRC1) in tumor tissues. ns, not significant ( P ≥ 0.05)

    Article Snippet: The primary antibodies included Cyclin D1 (Proteintech, China), GOT1 (ABclonal, China), GOT2 (ABclonal, China), MDH1 (ABclonal, China), MDH2 (ABclonal, China), OXPHOS Cocktail (Proteintech, China), and β-actin (Cell Signaling Technology, USA), all diluted 1:1000 in TBST containing 3% bovine serum albumin (BSA).

    Techniques: Standard Deviation, Immunofluorescence, Staining, Western Blot, Phospho-proteomics